| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5536198 | Tuberculosis | 2016 | 10 Pages |
Abstract
Our pilot data suggests that changes in the circulating BK and DABK levels in adult TB patients can be used as potential surrogate markers of the host response both early and late in anti-TB treatment for both pulmonary and extrapulmonary TB patients. We will further exploit these host-response signatures in the future as biomarkers in combination with other clinical and microbiologic tools which may improve treatment efficacy and facilitate the development of host-directed therapy.
Related Topics
Life Sciences
Immunology and Microbiology
Applied Microbiology and Biotechnology
Authors
Xu Qian, Duc T.M. Nguyen, Yaojun Li, Jianxin Lyu, Edward A. Graviss, Tony Y. Hu,